{
    "id": 2035,
    "fullName": "SMO D473H",
    "impact": "missense",
    "proteinEffect": "no effect - predicted",
    "geneVariantDescriptions": [
        {
            "description": "SMO D473H lies within the ligand-binding pocket of the Smo protein (PMID: 25759020). D473H shows similar activity to wild-type Smo in cell culture, and therefore, is predicted to have no effect on Smo protein function, but has been demonstrated to confer resistance to Hedgehog pathway inhibitors (PMID: 19726788, PMID: 29175550).",
            "references": [
                {
                    "id": 2677,
                    "pubMedId": 25759020,
                    "title": "Smoothened variants explain the majority of drug resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759020"
                },
                {
                    "id": 885,
                    "pubMedId": 19726788,
                    "title": "Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19726788"
                },
                {
                    "id": 12486,
                    "pubMedId": 29175550,
                    "title": "Molecular modeling study on resistance of WT/D473H SMO to antagonists LDE-225 and LEQ-506.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29175550"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6608,
        "geneSymbol": "SMO",
        "terms": [
            "SMO",
            "CRJS",
            "FZD11",
            "Gx",
            "SMOH"
        ]
    },
    "variant": "D473H",
    "createDate": "10/02/2014",
    "updateDate": "09/24/2019",
    "referenceTranscriptCoordinates": {
        "id": 123175,
        "transcript": "NM_005631",
        "gDna": "chr7:g.129209348G>C",
        "cDna": "c.1417G>C",
        "protein": "p.D473H",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6074,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-441 inhibited Gli-reporter activation in cells transfected with SMO D473H in culture (PMID: 24291104).",
            "molecularProfile": {
                "id": 1973,
                "profileName": "SMO D473H"
            },
            "therapy": {
                "id": 2425,
                "therapyName": "TAK-441",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5273,
                    "pubMedId": 24291104,
                    "title": "Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24291104"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4279,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient harboring SMO D473H with resistance to Erivedge (vismodegib) (PMID: 26546616).",
            "molecularProfile": {
                "id": 1973,
                "profileName": "SMO D473H"
            },
            "therapy": {
                "id": 1428,
                "therapyName": "Sonidegib",
                "synonyms": null
            },
            "indication": {
                "id": 2513,
                "name": "basal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4477,
                    "pubMedId": 26546616,
                    "title": "An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26546616"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1141,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY2940680, inhibited the activity of SMO D473H, which is a mutant that confers resistance to the treatment of vismodegib (Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, Abstract #2819).",
            "molecularProfile": {
                "id": 1973,
                "profileName": "SMO D473H"
            },
            "therapy": {
                "id": 1587,
                "therapyName": "Taladegib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 883,
                    "pubMedId": null,
                    "title": "Abstract 2819: Identification and characterization of a novel smoothened antagonist for the treatment of cancer with deregulated hedgehog signaling",
                    "url": "https://cancerres.aacrjournals.org/content/71/8_Supplement/2819"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1142,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, SMO D473H was identified in a medulloblastoma patient harboring PTCH1 W844C with secondary resistance to Erivedge (vismodegib) (PMID: 19726788).",
            "molecularProfile": {
                "id": 31759,
                "profileName": "PTCH1 W844C SMO D473H"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 885,
                    "pubMedId": 19726788,
                    "title": "Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19726788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1973,
            "profileName": "SMO D473H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31759,
            "profileName": "PTCH1 W844C SMO D473H",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 123175,
            "transcript": "NM_005631",
            "gDna": "chr7:g.129209348G>C",
            "cDna": "c.1417G>C",
            "protein": "p.D473H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}